MCID: PRS012
MIFTS: 48

Pars Planitis

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Pars Planitis

MalaCards integrated aliases for Pars Planitis:

Name: Pars Planitis 53 12 72 49 41 14 69
Vitritis 49 69
Peripheral Retinal Inflammation 49
Uveitis, Intermediate 69
Intermediate Uveitis 49
Posterior Cyclitis 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

OMIM 53 606177
Disease Ontology 12 DOID:12731
ICD10 32 H30.2
ICD9CM 34 363.21
MeSH 41 D015868
NCIt 46 C34903
MedGen 39 C0030593

Summaries for Pars Planitis

NIH Rare Diseases : 49 Pars planitis is a disease of the eye that is characterized by inflammation of the narrowed area (pars plana) between the colored part of the eye (iris) and the choroid. This may lead to blurred vision; dark, floating spots in the vision; and progressive vision loss. As the condition advances, cataracts, retinal detachment, or macular edema (fluid within the retina) may develop. Pars planitis most often affects young men and is generally not associated with any other disease or symptoms (idiopathic); however, it can be associated with other autoimmune conditions such as multiple sclerosis and sarcoidosis. Treatment typically includes corticosteroid drugs, immunosuppressive medications, and/or surgery. Last updated: 6/23/2015

MalaCards based summary : Pars Planitis, also known as vitritis, is related to retinal vasculitis and uveitis. An important gene associated with Pars Planitis is HLA-A (Major Histocompatibility Complex, Class I, A), and among its related pathways/superpathways are Allograft rejection and Influenza A. The drugs Dexamethasone and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary sites... more...

Description from OMIM: 606177

Related Diseases for Pars Planitis

Diseases related to Pars Planitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 retinal vasculitis 11.2
2 uveitis 10.3
3 multiple sclerosis 10.2
4 cataract 10.2
5 intermediate uveitis 10.2
6 palindromic rheumatism 10.2 HLA-A HLA-DRB1
7 microscopic polyangiitis 10.2 HLA-B HLA-DRB1
8 idiopathic inflammatory myopathy 10.2 HLA-B HLA-DRB1
9 rheumatic heart disease 10.2 HLA-A HLA-DRB1
10 phenytoin or carbamazepine toxicity 10.2 HLA-A HLA-B
11 dengue hemorrhagic fever 10.2 HLA-A HLA-DRB1
12 retinal detachment 10.2
13 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
14 retinitis 10.2
15 atrial tachyarrhythmia with short pr interval 10.2 HLA-A HLA-B
16 glaucomatocyclitic crisis 10.2 HLA-A HLA-B
17 panuveitis 10.2 HLA-B HLA-DRB1
18 anterior uveitis 10.2 HLA-A HLA-B
19 chronic pyelonephritis 10.2 HLA-A HLA-B
20 human herpesvirus 8 10.2 HLA-A HLA-B
21 idiopathic neutropenia 10.2 HLA-DRB1 IL1RN
22 echinococcosis 10.1 HLA-B HLA-DRB1
23 hematopoietic stem cell transplantation 10.1 HLA-A HLA-B
24 separation anxiety disorder 10.1 HLA-A HLA-B
25 temporal arteritis 10.1 HLA-DRB1 IL1RN
26 sclerosing cholangitis 10.1 HLA-B HLA-DRB1
27 bone inflammation disease 10.1 HLA-DRB1 IL1RN
28 retinoschisis 1, x-linked, juvenile 10.1
29 hydrops, lactic acidosis, and sideroblastic anemia 10.1
30 macular retinal edema 10.1
31 iridocyclitis 10.1
32 spondyloarthropathy 10.1 HLA-A HLA-B
33 severe cutaneous adverse reaction 10.1 HLA-A HLA-B
34 helicobacter pylori infection 10.1 HLA-DRB1 IL1RN
35 autoimmune hepatitis 10.1 HLA-A HLA-DRB1
36 juvenile rheumatoid arthritis 10.1 HLA-DRB1 IL1RN
37 cholangitis 10.0 HLA-B HLA-DRB1
38 spondyloarthropathy 1 10.0 HLA-B IL1RN
39 alopecia areata 10.0 HLA-A IL1RN
40 rheumatic disease 10.0 HLA-B HLA-DRB1
41 blood group, i system 9.9
42 crohn's disease 9.9
43 cone dystrophy 9.9
44 choroiditis 9.9
45 posterior uveitis 9.9
46 corneal ectasia 9.9
47 demyelinating disease 9.9
48 macular holes 9.9
49 acute zonal occult outer retinopathy 9.9
50 postherpetic neuralgia 9.9 HLA-A HLA-B HLA-DRB1

Graphical network of the top 20 diseases related to Pars Planitis:



Diseases related to Pars Planitis

Symptoms & Phenotypes for Pars Planitis

Clinical features from OMIM:

606177

GenomeRNAi Phenotypes related to Pars Planitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.88 HLA-B HLA-A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.88 HLA-B HLA-A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.88 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.88 HLA-B HLA-A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.88 HLA-B HLA-A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.88 HLA-B HLA-A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.88 HLA-B HLA-A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.88 HLA-B HLA-A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.88 HLA-B HLA-A

Drugs & Therapeutics for Pars Planitis

Drugs for Pars Planitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
3
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Chlorambucil Approved Phase 4 305-03-3 2708
6
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
8
Azathioprine Approved Phase 4 446-86-6 2265
9
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
10
Daclizumab Approved, Investigational Phase 4 152923-56-3
11
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3 67-73-2 6215
12
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
17 beta-endorphin Phase 4,Phase 2
18 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
19 Alkylating Agents Phase 4
20 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
21
protease inhibitors Phase 4,Phase 2,Phase 3
22 Adrenocorticotropic Hormone Phase 4,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Cyclosporins Phase 4
25 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
32 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
35 Melanocyte-Stimulating Hormones Phase 4,Phase 2
36 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Antitubercular Agents Phase 4,Phase 3
40
Adalimumab Approved Phase 3 331731-18-1 16219006
41
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
42
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
43
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
44
Difluprednate Approved Phase 3 23674-86-4 443936
45
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
47 triamcinolone acetonide Phase 3,Phase 1,Phase 2
48 Prednisolone acetate Phase 3
49 interferons Phase 3,Phase 1,Phase 2
50 Methylprednisolone acetate Phase 3

Interventional clinical trials:

(show top 50) (show all 57)

# Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
4 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
5 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
6 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
7 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
8 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
9 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
10 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
11 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
12 Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery Completed NCT01124045 Phase 3 Difluprednate ophthalmic emulsion, 0.05%;Prednisolone acetate ophthalmic suspension, 1.0%
13 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT02748512 Phase 3 FAI insert
14 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
15 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
16 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Active, not recruiting NCT03097315 Phase 3
17 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Active, not recruiting NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
18 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Active, not recruiting NCT01148225 Phase 3 adalimumab
19 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
20 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
21 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
22 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
23 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01103024 Phase 3
24 Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
25 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
26 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
27 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
28 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis Withdrawn NCT01327664 Phase 3
29 Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Completed NCT00615693 Phase 2 AEB071
30 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
31 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
32 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
33 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
34 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
35 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
36 Leflunomide to Treat Uveitis Completed NCT00001863 Phase 2 Leflunomide
37 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
38 Intravitreal Sirolimus as Therapeutic Approach to Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
39 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Recruiting NCT02911116 Phase 2 Ustekinumab
40 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Recruiting NCT02863809 Phase 1, Phase 2 Riboflavin;Dextran
41 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Active, not recruiting NCT01717170 Phase 1, Phase 2 Tocilizumab
42 ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) Not yet recruiting NCT02931175 Phase 2 ACTH gel
43 Safety and Preliminary Efficacy Study of V404 PDS in Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
44 Safety &Efficacy of CF101 to Subjects With Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
45 A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Withdrawn NCT00499551 Phase 1, Phase 2
46 Sirolimus as Therapeutic Approach to Uveitis Unknown status NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
47 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b
48 Quality of Life in Patients With Intermediate Uveitis Completed NCT01314469
49 Retisert and Cataract Surgery in Patients With Severe Uveitis Completed NCT00570830
50 Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With Papilloedema Completed NCT01170481

Search NIH Clinical Center for Pars Planitis

Cochrane evidence based reviews: pars planitis

Genetic Tests for Pars Planitis

Anatomical Context for Pars Planitis

MalaCards organs/tissues related to Pars Planitis:

38
Eye, Retina, Endothelial, Testes, T Cells

Publications for Pars Planitis

Articles related to Pars Planitis:

(show top 50) (show all 100)
# Title Authors Year
1
Outcomes of cataract surgery with/without vitrectomy in patients with pars planitis and immunosuppressive therapy. ( 28396945 )
2017
2
Analysis of clinical features and visual outcomes of pars planitis. ( 28389773 )
2017
3
Challenges with cataract surgery in pars planitis patients. ( 28593425 )
2017
4
Pars Planitis ( 28613790 )
2017
5
Scleral Buckling for Rhegmatogenous Retinal Detachment Associated with Pars Planitis. ( 27688907 )
2016
6
Retinoschisis in Pars Planitis. ( 26902143 )
2016
7
Peripheral Cryoablation for Treatment of Active Pars Planitis: Long-Term Outcomes of a Retrospective Study. ( 26576712 )
2016
8
A 12-Year-Old Boy with Pars Planitis. ( 26587811 )
2015
9
Rhegmatogenous retinal detachment due to a macular hole in a patient with pars planitis: a case report. ( 25565856 )
2015
10
Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis. ( 27051493 )
2015
11
Immunopathogenic Background of Pars Planitis. ( 26438050 )
2015
12
Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico. ( 24985727 )
2014
13
Association of epiretinal membranes with macular edema in pars planitis. ( 24332688 )
2013
14
Peripapillary choroidal neovascularization in pars planitis. ( 23514324 )
2013
15
Four years old, one eye, pars planitis and cataract: surgical challenges give challenging surprises. ( 23626571 )
2013
16
Corneal ectasia secondary to peripheral endotheliopathy in a patient with classic pars planitis. ( 21484170 )
2011
17
Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( 21034305 )
2011
18
Childhood pars planitis; clinical features and outcomes. ( 22454747 )
2011
19
[Clinical and epidemiological features and HLA association in patients with pars planitis]. ( 20537664 )
2010
20
Peptidic sequence "HSEAETGPP" is recognized by the sera of pars planitis patients. ( 19480736 )
2009
21
Pars planitis: a 20-year study of incidence, clinical features, and outcomes. ( 18724984 )
2008
22
Acute zonal occult outer retinopathy (AZOOR) and pars planitis: a new association? ( 18369082 )
2008
23
Pars planitis: a 20-year study of incidence, clinical features, and outcomes. ( 18036872 )
2007
24
Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. ( 17913171 )
2007
25
Pars planitis is associated with an increased frequency of effector-memory CD57+ T cells. ( 17475702 )
2007
26
The enigma of pars planitis, revisited. ( 16564810 )
2006
27
Clinical symptoms and complications of pars planitis in childhood. ( 15849986 )
2005
28
Valsalva retinopathy: diagnostic challenges in a patient with pars-planitis. ( 15799745 )
2005
29
The appearance of pars planitis in multiple sclerosis. ( 16117323 )
2005
30
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. ( 15385196 )
2004
31
Phacoemulsification with intraocular lens implantation in cases of pars planitis. ( 15474816 )
2004
32
Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. ( 12854027 )
2003
33
Classic Pars Planitis: strong correlation of class II genes with gender and some clinical features in Mexican Mestizos. ( 14522094 )
2003
34
Genetic polymorphism of HLA DR in a Scottish population of patients with pars planitis. ( 12841565 )
2003
35
Vitreous hemorrhage is a common complication of pediatric pars planitis. ( 11772586 )
2002
36
Peripheral retinoschisis and exudative retinal detachment in pars planitis. ( 12476097 )
2002
37
An old crone finds a new home: Crohn's disease and pars planitis. ( 12789592 )
2002
38
Grading of pars planitis by ultrasound biomicroscopy--echographic and clinical study. ( 12423740 )
2002
39
Vitrectomy for pars planitis complicated by vitreous hemorrhage: visual outcome and long-term follow-up. ( 11292422 )
2001
40
Pars planitis: a comparison of childhood onset and adult onset disease. ( 11341451 )
2001
41
Pars planitis: epidemiology, treatment, and association with multiple sclerosis. ( 11449325 )
2001
42
The association of HLA class II with pars planitis. ( 11336946 )
2001
43
Ultrasound biomicroscopy in the diagnosis and management of pars planitis caused by caterpillar hairs. ( 11004275 )
2000
44
Coats'-like response in pars planitis. ( 10048380 )
1999
45
Visual outcomes after pars plana vitrectomy for epiretinal membranes associated with pars planitis. ( 10366075 )
1999
46
Pars planitis: clinical features and class II HLA associations. ( 10080220 )
1999
47
Results of peripheral laser photocoagulation in pars planitis. ( 10360286 )
1998
48
Intermediate uveitis of pars planitis type in identical twins. Report of a case. ( 10826543 )
1998
49
Familial pars planitis and dominant optic atrophy. ( 9134550 )
1997
50
Blood serum interleukin-1 receptor antagonist in pars planitis and ocular BehAset disease. ( 9152064 )
1997

Variations for Pars Planitis

Expression for Pars Planitis

Search GEO for disease gene expression data for Pars Planitis.

Pathways for Pars Planitis

GO Terms for Pars Planitis

Cellular components related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.85 CCR7 CD27 HLA-A HLA-B HLA-DRB1 IL1RN
2 extracellular exosome GO:0070062 9.8 CD27 HLA-A HLA-B HLA-DRB1 IL1RN
3 Golgi membrane GO:0000139 9.65 HLA-A HLA-B HLA-DRB1
4 external side of plasma membrane GO:0009897 9.5 CCR7 CD27 HLA-DRB1
5 phagocytic vesicle membrane GO:0030670 9.46 HLA-A HLA-B
6 recycling endosome membrane GO:0055038 9.43 HLA-A HLA-B
7 cell surface GO:0009986 9.35 CCR7 CD27 HLA-A HLA-B HLA-DRB1
8 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-A HLA-B HLA-DRB1
9 MHC class I protein complex GO:0042612 9.26 HLA-A HLA-B
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-A HLA-B HLA-DRB1

Biological processes related to Pars Planitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.69 HLA-A HLA-B HLA-DRB1
2 viral process GO:0016032 9.63 HLA-A HLA-B HLA-DRB1
3 inflammatory response GO:0006954 9.58 CCR7 CD27 IL1RN
4 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.49 HLA-A HLA-B
5 positive regulation of JNK cascade GO:0046330 9.48 CCR7 CD27
6 type I interferon signaling pathway GO:0060337 9.43 HLA-A HLA-B
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.37 HLA-A HLA-B
8 interferon-gamma-mediated signaling pathway GO:0060333 9.33 HLA-A HLA-B HLA-DRB1
9 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.32 HLA-A HLA-B
10 protection from natural killer cell mediated cytotoxicity GO:0042270 9.26 HLA-A HLA-B
11 antigen processing and presentation GO:0019882 9.13 HLA-A HLA-B HLA-DRB1
12 immune response GO:0006955 9.1 CCR7 CD27 HLA-A HLA-B HLA-DRB1 IL1RN

Molecular functions related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-DRB1

Sources for Pars Planitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....